Psoriasis

Lexette Foam Now Available for Plaque Psoriasis

Lexette Foam Now Available for Plaque Psoriasis

By

Lexette (halobetasol propionate) foam 0.05% has been made available for patients 18 years of age and older for the topical treatment of plaque psoriasis.

Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies

Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies

By

This systematic review was limited by literature that was lacking in survival analyses and inconsistent definitions of drug discontinuation across the literature.

Psoriasis Tx Linked to Drop in Noncalcified Coronary Plaque

Psoriasis Tx Linked to Drop in Noncalcified Coronary Plaque

Treatment of psoriasis with biologic therapy is associated with a reduction in noncalcified coronary plaque and improved plaque morphology.

Psoriasis, Especially Severe Disease, Associated With Increased Risk for All-Cause Mortality

Psoriasis, Especially Severe Disease, Associated With Increased Risk for All-Cause Mortality

By

Patients with psoriasis, particularly those with risk factors and severe disease, should receive appropriate screening and preventative intervention.

Calcipotriol Plus Betamethasone Dipropionate Foam Offers Rapid, Effective Itch Relief in Psoriasis

Calcipotriol Plus Betamethasone Dipropionate Foam Offers Rapid, Effective Itch Relief in Psoriasis

By

Compared with foam vehicle, calcipotriol plus betamethasone dipropionate foam offers more rapid and effective itch relief, with associated significant improvements in sleep and Dermatology Life Quality Index scores.

Examining Molecular, Histopathologic Changes With Risankizumab vs Ustekinumab in Psoriasis

Examining Molecular, Histopathologic Changes With Risankizumab vs Ustekinumab in Psoriasis

By

Investigators observed differences and similarities in molecular and histopathologic profiles in skin lesions of patients with psoriasis treated with risankizumab vs ustekinumab.

Methotrexate Well Tolerated, Effective for Psoriasis in Chinese

Methotrexate Well Tolerated, Effective for Psoriasis in Chinese

Methotrexate is well tolerated and effective for psoriasis in a Chinese population and is more effective for those without psoriatic arthritis.

Improved Health Literacy Could Be Beneficial for Psoriasis Care

Improved Health Literacy Could Be Beneficial for Psoriasis Care

By

Further research is needed to analyze the mechanisms that are needed for an effective intervention program.

Clinical Challenge: Addressing Psoriasis and Comorbid Obesity

Clinical Challenge: Addressing Psoriasis and Comorbid Obesity

By

Obesity is an independent risk factor for the development of psoriasis and is associated with a worse prognosis.

Secukinumab Associated With QoL Improvements in Pooled Psoriasis Data

Secukinumab Associated With QoL Improvements in Pooled Psoriasis Data

By

In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12.

<i>HLA-C*06:02</i> Status May Be Predictive of Psoriasis Treatment Response

HLA-C*06:02 Status May Be Predictive of Psoriasis Treatment Response

By

HLA-C*06:02 status is a predictive biomarker that influences response to adalimumab and ustekinumab in patients with psoriasis.

Desoximetasone Spray Effective for Treatment-Resistant Psoriasis and Atopic Dermatitis

Desoximetasone Spray Effective for Treatment-Resistant Psoriasis and Atopic Dermatitis

By

Desoximetasone with and without phone reminders was associated with clinical improvement in both psoriasis and atopic dermatitis.

Combination HP/TAZ Lotion Offers Rapid and Significant Relief of Psoriasis Symptoms

Combination HP/TAZ Lotion Offers Rapid and Significant Relief of Psoriasis Symptoms

By

Fixed-combination HP/TAZ lotion to manage moderate to severe plaque psoriasis was effective and superior to individual active ingredients.

Topical Cal/BD Foam Efficacious for the Rapid Relief of Severe Itch in Psoriasis

Topical Cal/BD Foam Efficacious for the Rapid Relief of Severe Itch in Psoriasis

By

Investigators noted that itch-related improvements occurred before treatment efficacy was observed using modified PASI scores.

Switching Therapeutic Class in Psoriasis Linked to Better Treatment Efficacy

Switching Therapeutic Class in Psoriasis Linked to Better Treatment Efficacy

By

The investigators sought to describe switching patterns in dermatologic real-life daily practice among patients with psoriasis.

Increased Risk for Incident Thyroid Disease in Psoriasis

Increased Risk for Incident Thyroid Disease in Psoriasis

By

An endocrinology consultation should be considered in patients with psoriatic disease who present with thyroid symptoms.

Comorbid Metabolic Syndrome, Psoriatic Arthritis Linked to Reduced Health-Related Quality of Life

Comorbid Metabolic Syndrome, Psoriatic Arthritis Linked to Reduced Health-Related Quality of Life

By

Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.

Treatment Satisfaction Lacking Among Patients With Psoriasis, Psoriatic Arthritis

Treatment Satisfaction Lacking Among Patients With Psoriasis, Psoriatic Arthritis

By

Considerable numbers of patients with psoriasis and/or psoriatic arthritis in Denmark, Norway, and Sweden are not receiving optimal therapy, according to results of a Scandinavian survey.

Hypertension With Psoriasis Tied to More Cardiac Interventions

Hypertension With Psoriasis Tied to More Cardiac Interventions

Psoriasis is associated with an increased risk for cardiovascular interventions in patients with hypertension.

Classification of Psoriasis Severity Depends on Definition

Classification of Psoriasis Severity Depends on Definition

Depending on the definition used, there are large variations in the proportion of patients identified as having moderate-to-severe psoriasis.

Prevalence of Hidradenitis Suppurativa Increased in Patients With Psoriasis

Prevalence of Hidradenitis Suppurativa Increased in Patients With Psoriasis

By

Results showed that HS prevalence was increased in patients with psoriasis when compared with the control participants.

Risk for Adverse Events Same or Lower With Biologics vs Conventional Systemic/Topical Therapies for Psoriasis

Risk for Adverse Events Same or Lower With Biologics vs Conventional Systemic/Topical Therapies for Psoriasis

By

Compared with conventional systemic/topical therapies, biologic therapies were associated with similar or lower risk for adverse medical conditions in people with psoriasis.

Long-Term Ixekizumab Treatment Acceptably Safe in Plaque Psoriasis

Long-Term Ixekizumab Treatment Acceptably Safe in Plaque Psoriasis

By

Patients with moderate to severe plaque psoriasis typically require long-term treatment to achieve disease control.

TNFi Treatment Patterns Examined Among Pregnant Women

TNFi Treatment Patterns Examined Among Pregnant Women

By

Using a validated claims-based algorithm, study authors identified pregnancies among women 15-54 years of age from the US Sentinel System between January 1 2004 and September 30 2015.

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

By

The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.

Patient Needs, Treatment Goals in Psoriasis Vary by Gender and Age

Patient Needs, Treatment Goals in Psoriasis Vary by Gender and Age

By

During consultation, physicians need to assess the best individual psoriasis treatment option based on the individual patient needs.

Guselkumab Compared With Secukinumab in Head-to-Head Plaque Psoriasis Trial

Guselkumab Compared With Secukinumab in Head-to-Head Plaque Psoriasis Trial

By

In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at weeks 0, 1, 2 3, 4 followed by every 4-week dosing.

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

By

The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.

Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis

Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis

By

The ability of secukinumab vs placebo to clear nail psoriasis was evaluated using the Nail Psoriasis Severity Index.

Clinical Response Evaluated After Withdrawal, Retreatment With Ixekizumab in Plaque Psoriasis

Clinical Response Evaluated After Withdrawal, Retreatment With Ixekizumab in Plaque Psoriasis

By

Investigators evaluated the effect of ixekizumab withdrawal and retreatment in Japanese patients with plaque psoriasis in this single-arm open-label phase 3 study.

Sign up for Newsletters